Gourt > Health > Pharmacy > Drugs and Medications > I > Imatinib
| | |
| CAS number 152459-95-5 (imatinib) 220127-57-1 (imatinib mesilate) | ATC code L01XX28 |
| Chemical formula | C29H31N7O.CH4SO3 |
| Molecular weight | 589.7 |
| Bioavailability | 98% |
| Metabolism | Hepatic, mainly CYP3A4 |
| Elimination half-life | 18 hours |
| Excretion | Hepatic |
| Pregnancy category | D (Australia) |
| Legal status | ? |
| Routes of administration | Oral |
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec® (USA) or Glivec® (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally still referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of simply inhibiting rapidly dividing cells.
More on [ Imatinib ]
RT @OncologySTAT: This Week's Top Journal Scan: Dasatinib in Imatinib-Resistant, BCR-ABLâMutated CML http://tinyurl.com/yglqbgd
knwachter (Kerri Wachter) Wed, 04 Nov 2009 16:04:23 -0000
RT @OncologySTAT: This Week's Top Journal Scan: Dasatinib in Imatinib-Resistant, BCR-ABL–Mutated CML http://tinyurl.com/yglqbgd
This Week's Top Journal Scan: Dasatinib in Imatinib-Resistant, BCR-ABLâMutated CML http://tinyurl.com/yglqbgd
oncologystat (OncologySTAT) Wed, 04 Nov 2009 15:33:41 -0000
This Week's Top Journal Scan: Dasatinib in Imatinib-Resistant, BCR-ABL–Mutated CML http://tinyurl.com/yglqbgd
RT @ChemicalBiology: A Conversation With Brian J. Druker, co-developer of imatinib http://www.nytimes.com/2009/11/03/science/03conv.html
bstockwell (Brent Stockwell) Wed, 04 Nov 2009 01:15:32 -0000
RT @ChemicalBiology: A Conversation With Brian J. Druker, co-developer of imatinib http://www.nytimes.com/2009/11/03/science/03conv.html
Science News Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia http://bit.ly/18jo7R
sciencestage (ScienceStage) Sun, 01 Nov 2009 22:33:09 -0000
Science News Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia http://bit.ly/18jo7R
TARGETS AND EFFECTORS OF THE CELLULAR RESPONSE TO AURORA KINASE INHIBITOR MK-0457 (VX-680) IN IMATINIB SEN...: - http://tinyurl.com/yeaxd3r
research_papers (qasim) Sun, 01 Nov 2009 04:59:07 -0000
TARGETS AND EFFECTORS OF THE CELLULAR RESPONSE TO AURORA KINASE INHIBITOR MK-0457 (VX-680) IN IMATINIB SEN...: - http://tinyurl.com/yeaxd3r
Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography...: - http://tinyurl.com/yly8mjs
research_papers (qasim) Sat, 31 Oct 2009 09:53:37 -0000
Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography...: - http://tinyurl.com/yly8mjs
DrugDigest: Imatinib ( Gleevec ) - Information on dosage, usage, side effects, interactions, and drug comparisons including generics when available.
Gleevec - Imatinib mesylate. Features prescribing and reimbursement information for US residents.
Meta Description: [ How Gleevec works. Gleevec is used to treat Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). ]
Gleevec Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
Gleevec Information - Features information from the FDA's Center for Drug Evaluation and Research including news releases, FAQs, approval letter, and draft package insert.
Meta Description: [ REPLACE WITH VERBOSE DESCRIPTION ]
Gleevec Resource Center - Features articles, news releases, FAQs, and drug information.
Meta Description: [ Chronic Myelogenous Leukemia Support Home Page. ]
Gleevec's Glory Days - Howard Hughes Medical Institute article, available in HTML and PDF format.
Imatinib ( Glivec ) - International Site - Manufacturer's information on this prescription medication used in the treatment of Chronic Myelogenous Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST).
Meta Description: [ Glivec is a prescription medication used in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) from Novartis Oncology. On glivec.com international healthcare professionals can learn about CML and GIST, as well as find information on how Glivec treats th... ]
Leukemia-Treatment - Site contains information on Gleevec, CML-Chronic Myeloid Leukemia with monthly updates on new developments from Dr. Brian Druker.
Life Raft Group - Features newsletters from this group of patients who are taking part in the Gleevec trials to treat gastrointestinal stromal tumors, a form of cancer.
Meta Description: [ The Life Raft Group. A patient/caregiver support group for GIST cancer. ]
Newcastle CML - Press release about the STI571 trials in the UK.
Novartis Pharmaceuticals Canada: Gleevec - Prescribing and patient information, from the manufacturer.
Meta Description: [ Novartis Pharmaceuticals Canada Inc. - Our Products - Gleevec ]
STI571 Digest - Reports, news releases, list of current drug trials, and articles from the NIH's National Cancer Institute.
Meta Description: [ A collection of material on STI571 (Gleevec), the first approved drug to directly turn off the signal of a protein known to cause a cancer. ]
Unofficial Gleevec Site - Features a history of the drug, interviews with medical professionals, message boards, FAQs, news, and an album of thank yous to Dr. Druker, Gleevec's primary researcher.
Meta Description: [ sti571, sti-571, Gleevec, Glivec, leukemia, chronic myelogenous leukemia, cml, gist, c-kit, gastrointestinal stromal tumor, leiomyosarcoma, cancer, tyrosine kinase inhibitor, cgp57148b, cgp57148, sti571, sti-571, Gleevec, Glivec, leukemia, chronic myelogenous leukemia, cml, gist, c-kit, gastroint... ]
Yahoo! Groups: Gleevec - Discussion forum for anyone interested in Gleevec treatments.
Meta Description: [ Gleevec: Gleevec ]
| Gleevec receives US approval as first treatment to ... | |
| Next Video | |
